MEF2A and hepatocellular carcinoma: The role of EGF receptor and the MEF2 family of transcription factors in the RENCA macrobead-induced growth inhibitory effect could also apply to in situ tumors of varying origins and genetic profiles; we have observed tumor marker changes, decreases in 18F-fluorodeoxyglucose uptake by the tumors, and tumor necrosis during Phase I clinical trials using RENCA macrobeads as a treatment for numerous tumors, including prostate, colorectal, and hepatocellular carcinoma, among others [33].